Currently out of the existing stock ratings of Eliana Merle, 78 are a BUY (71.56%), 31 are a HOLD (28.44%).

Eliana Merle

Work Performance Price Targets & Ratings Chart

Analyst Eliana Merle, currently employed at BARCLAYS, carries an average stock price target met ratio of 54.1% that have a potential upside of 53.51% achieved within 255 days. Previously, Eliana Merle worked at CANTOR FITZGERALD.

Eliana Merle’s has documented 291 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ANAB, AnaptysBio at 07-Jan-2026.

Wall Street Analyst Eliana Merle

Analyst best performing recommendations are on ZNTL (ZENTALIS PHARMACEUTICALS LLC).
The best stock recommendation documented was for ANAB (ANAPTYSBIO) at 11/7/2019. The price target of $28 was fulfilled within 1 day with a profit of $8.16 (22.57%) receiving and performance score of 225.66.

Average potential price target upside

of $123.03 (39.39%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $44.75 (55.76%) on BMRN (BIOMARIN PHARMACEUTICAL).
of $38.2 (58.51%) on MRNA (MODERNA).

APLS Apellis Pharmaceuticals ARVN Arvinas BBIO BridgeBio Pharma BNTX BioNTech SE CBAY Cymabay Therapeu DRRX Durect KDMN Kadmon Holdings ZNTL Zentalis Pharmaceuticals Llc ANAB AnaptysBio BMRN Biomarin Pharmaceutical GLPG Galapagos NV ADR GOSS Gossamer Bio IONS Ionis Pharmaceuticals MRNA Moderna QURE Uniqure NV ISEE IVERIC bio PRQR ProQR Therapeutics BV AKRO Akero Therapeutics ETNB 89bio KOD Kodiak Sciences KYMR Kymera Therapeutics MDGL Madrigal Pharmaceuticals RAPT RAPT Therapeutics TERN Terns Pharmaceuticals AADI Aadi Bioscience ALT Altimmune CVAC CureVac NV FOLD Amicus Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Tazeen Ahmad (BAML)